These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15555338)

  • 1. [Clinical significance of expression of PSA, hK2, PSMA in the peripheral blood of patients with prostate cancer].
    Cui WG; Zhao H; Song YZ; Zhang J; Zhang LG; Shi JD; Qiang WM
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):479-81. PubMed ID: 15555338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
    Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
    Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
    Xu T; Chen X; Wang XF; Hou SK; Zhu JC; Zhang XD; Huang XB
    Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):164-8. PubMed ID: 15100735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classification analyses for prostate cancer, benign prostate hyperplasia and healthy subjects by SERS-based immunoassay of multiple tumour markers.
    Zhou L; Liu Y; Wang F; Jia Z; Zhou J; Jiang T; Petti L; Chen Y; Xiong Q; Wang X
    Talanta; 2018 Oct; 188():238-244. PubMed ID: 30029370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis.
    Zhang L; Wang CY; Yang R; Shi J; Fu R; Chen L; Klocker H; Zhang J
    Urol Oncol; 2008; 26(6):634-40. PubMed ID: 18367130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
    Jemaa AB; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
    J Immunoassay Immunochem; 2014; 35(1):48-59. PubMed ID: 24063616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
    Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.
    Zhang Y; Zippe CD; Van Lente F; Klein EA; Gupta MK
    Clin Cancer Res; 1997 Jul; 3(7):1215-20. PubMed ID: 9815802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
    Ylikoski A; Pettersson K; Nurmi J; Irjala K; Karp M; Lilja H; Lövgren T; Nurmi M
    Clin Chem; 2002 Aug; 48(8):1265-71. PubMed ID: 12142383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction.
    Kusuda Y; Miyake H; Kurahashi T; Fujisawa M
    Urol Oncol; 2013 Jul; 31(5):615-21. PubMed ID: 21600799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA-PSMA profiles and their impact on sera PSA levels and angiogenic activity in hyperplasia and human prostate cancer.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
    Pathol Biol (Paris); 2014 Jun; 62(3):129-36. PubMed ID: 24745345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
    Magklara A; Scorilas A; Catalona WJ; Diamandis EP
    Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer.
    Mitsiades CS; Lembessis P; Sourla A; Milathianakis C; Tsintavis A; Koutsilieris M
    Clin Exp Metastasis; 2004; 21(6):495-505. PubMed ID: 15679047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
    Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
    Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
    Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
    Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.